Chemomab Therapeutics Announces Q3 EPS of 0.4c Compared to (1c) Last Year
Phase 3 Trial Preparation: Chemomab is advancing preparations for the nebokitug Phase 3 trial targeting primary sclerosing cholangitis, with positive discussions with the FDA and EMA.
Regulatory Support: Both the FDA and EMA have indicated that a single Phase 3 registration trial will suffice for approval, and a composite of clinically relevant events can be used as the study endpoint.
Trial Launch Expectations: Due to the alignment between the regulatory agencies and the advanced status of the trial design, Chemomab anticipates launching the trial as soon as possible.
Leadership Statement: Adi Mor, CEO of Chemomab, expressed satisfaction with the progress and support from regulatory bodies regarding the trial's design and requirements.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on CMMB
About CMMB
About the author
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Tilray Brands Surge: Tilray Brands, Inc. saw an 11.36% increase in after-hours trading, reaching $13.53, following a one-for-ten reverse stock split and positive investor sentiment regarding its restructuring and beverage portfolio.
Valneva's Positive Trial Results: Valneva SE's stock rose by 7.22% after hours to $9.31, buoyed by favorable final data from its Phase 2 chikungunya vaccine trial, which supports future Phase 3 development plans.
Chemomab and Genenta Recovery: Chemomab Therapeutics Ltd. gained 7.66% after hours to $2.39, while Genenta Science S.p.A. climbed 12.06% to $1.58, both recovering from earlier declines and reacting to recent clinical trial updates.
Kazia and Traws Pharma Movements: Kazia Therapeutics Limited increased by 10.93% after hours to $11.57, following a presentation on its cancer treatment, while Traws Pharma, despite no new developments, edged up 8.81% to $2.54, driven by low-float trading momentum.
Top Strong Buy Stocks for October 23: MQ, GES, and Others
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Marqeta, Guess?, The Travelers Companies, Chemomab Therapeutics, and Par Pacific Holdings, with significant increases in their earnings estimates over the past 60 days.
Quantum Computing Revolution: Quantum computing is rapidly advancing and is seen as the next major technological revolution, with major companies like Microsoft, Google, and Amazon integrating it into their infrastructure.
Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this emerging technology.
Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, providing additional insights for investors interested in these stocks.
